Zentalis Pharmaceuticals (ZNTL) Expected to Release Earnings on Wednesday

Zentalis Pharmaceuticals (NASDAQ:ZNTL) will likely be issuing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Zentalis Pharmaceuticals to announce earnings of ($0.45) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.01). On average, analysts expect Zentalis Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL opened at $4.74 on Monday. The business’s fifty day simple moving average is $4.24 and its two-hundred day simple moving average is $3.55. Zentalis Pharmaceuticals has a 12 month low of $1.21 and a 12 month high of $6.95. The company has a market cap of $337.44 million, a price-to-earnings ratio of -2.74 and a beta of 1.92.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ZNTL. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, May 22nd. Rodman & Renshaw started coverage on Zentalis Pharmaceuticals in a research report on Thursday, July 23rd. They set a “buy” rating and a $11.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a report on Monday, July 6th. Guggenheim boosted their target price on Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, April 10th. Finally, Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Sunday, May 31st. Four analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Zentalis Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $6.75.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. Voleon Capital Management LP bought a new position in shares of Zentalis Pharmaceuticals in the third quarter worth approximately $41,000. Qube Research & Technologies Ltd bought a new stake in shares of Zentalis Pharmaceuticals during the 2nd quarter valued at $37,000. Algert Global LLC bought a new stake in shares of Zentalis Pharmaceuticals during the 3rd quarter valued at $73,000. Corient Private Wealth LLC purchased a new position in shares of Zentalis Pharmaceuticals during the 2nd quarter valued at $83,000. Finally, Opal Capital LLC purchased a new position in shares of Zentalis Pharmaceuticals during the 4th quarter valued at $98,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.